Idogen AB Interim report January 1 - March 31, 2020
First quarter (January-March 2020)
  •     Other operating income amounted to KSEK 1 414 (854)

  •     Operating loss was KSEK -6 634 (-6 762).

  •     Loss for the period totalled KSEK -6 220 (-6 653)

  •     Cash flow from operating activities was KSEK -1 786 (-12 031)

  •     Loss per share was SEK -0.13 (-0.14)


Significant events in the first quarter
  •     In January, the company announced a decision regarding a rights issue in a gross amount of MSEK 29.

  •     Idogen was visited by the Crown Princecess and Prince Daniel at the end of January with the purpose to learn more about Idogen's tolerogenic cell therapy.

  •     An Extraordinary General Meeting was held on 17 February in Lund, which approved the share issue.

  •     The issue was completed in March , uderwritten by 88 % and generated MSEK 20.6 gross for Idogen.

  •     In March, disbursements from the EU for Horizon 2020 were resumed and KEUR 550 was disbursed during the month.


Significant events after the end of the period
  •     To date, the ongoing corona pandemic has had a minor impact on the company's operations. If the reduction in societal functions continues or is extended, there is, however,  a risk of further impact.

  •     No other significant events occurred after the end of the period that affected the results or financial position.

If you have any questions, please contact:
Anders Karlsson, Chief Executive Officer
Phone: +46 (0) 709 18 00 10


Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.

Source: Cision

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr


Redan prenumerant?